| abstract |
1.- A product comprising serotonin assimilation inhibitor (lAS) and a 5HT1a antagonist as a combination prepared for simultaneous, separate, or sequential use in the treatment and / or prevention of vasomotor instability. 2.- The product according to claim 1, characterized in that said lAS is selected from the group consisting of fluoxetine, paroxetine, sertraline, fluvoxamine, duloxetine, amoxapine, doxepin, bupropion, citaloprom and amitriptyline.3.- The product according to claim 1 or the claim 2, characterized in that the 5HT1a antagonist is selected from the group consisting of (N- [2- [4- (2-methoxyphenyl) -1-piperazinyl [ethyl] -N-2-pyridinylcyclohexanecarboxamide), (R) -N- (2-methyl- (4-indolyl-1-piperazinyl) ethyl) -N- (2-pyridinyl) cyclohexanecarboxamide and NAD-299.4.- The use of a 5HT2a agonist in the manufacture of a medicament for the treatment and / or Vasomotor instability prevention. |